Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases (Associated Press)

The IL-11 inhibitor antibody is the first of its kind to reach clinical development stage and is based on a partnership between the Company and Enleofen Bio Pte. Ltd. (Enleofen), with a goal to improve patient outcomes.